Actively Recruiting
Using 68Ga-grazytracer PET Scans to Monitor Immunotherapy in Adults with Stage III Non-Small-Cell Lung Cancer
Led by Ruijin Hospital · Updated on 2024-10-02
30
Participants Needed
1
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of 68Ga-grazytracer PET imaging to monitor immune responses in patients with stage III non-small cell lung cancer NSCLC receiving neoadjuvant immunotherapy. This approach aims to improve how doctors detect CD8 T cell activity in tumors, which may help in evaluating treatment effectiveness and guide clinical decisions. The study focuses on how this imaging technique can enhance the assessment of pathological responses and event-free survival in this patient group. This observational study involves patients with stage III NSCLC who are planned to undergo neoadjuvant immunotherapy. The main intervention is the use of 68Ga-grazytracer PET scans to detect immune cell aggregation in the tumor area after treatment. There are no treatment groups or drug interventions as this study primarily observes and evaluates the imaging methods predictive value before surgery and over a three-year period. Participants will undergo PET imaging and clinical assessments to measure the aggregation of CD8 T cells in their tumors after immunotherapy. The study will track outcomes including the predictive performance of the imaging up to the time of surgery and over a three-year follow-up. Researchers will also monitor overall compliance and safety throughout the study, which is expected to help improve future treatment monitoring strategies for NSCLC patients.
CONDITIONS
Brief Title
The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here